Cargando…
All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex
BACKGROUND: Decitabine (DAC) is used as the first-line therapy in patients with higher-risk myelodysplastic syndromes (HR-MDS) and elderly acute myeloid leukaemia (AML) patients unsuitable for intensive chemotherapy. However, the clinical outcomes of patients treated with DAC as a monotherapy are fa...
Autores principales: | Wang, Lu, Zhang, Qi, Ye, Li, Ye, Xingnong, Yang, Wenli, Zhang, Hua, Zhou, Xinping, Ren, Yanling, Ma, Liya, Zhang, Xiang, Mei, Chen, Xu, Gaixiang, Li, Kongfei, Luo, Yingwan, Jiang, Lingxu, Lin, Peipei, Zhu, Shuanghong, Lang, Wei, Wang, Yuxia, Shen, Chuying, Han, Yueyuan, Liu, Xiaozhen, Yang, Haiyang, Lu, Chenxi, Sun, Jie, Jin, Jie, Tong, Hongyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938271/ https://www.ncbi.nlm.nih.gov/pubmed/36482192 http://dx.doi.org/10.1038/s41416-022-02074-0 |
Ejemplares similares
-
Mutation status and burden can improve prognostic prediction of patients with lower‐risk myelodysplastic syndromes
por: Jiang, Lingxu, et al.
Publicado: (2019) -
Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone
por: Ye, Li, et al.
Publicado: (2017) -
Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes
por: Yan, Xuefen, et al.
Publicado: (2021) -
Serial monitoring of circulating tumour DNA on clinical outcome in myelodysplastic syndromes and acute myeloid leukaemia
por: Zhou, Xinping, et al.
Publicado: (2023) -
Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms
por: Ye, Xingnong, et al.
Publicado: (2017)